Literature DB >> 16382127

Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma.

Ye-Xiong Li1, Bo Yao, Jing Jin, Wei-Hu Wang, Yue-Ping Liu, Yong-Wen Song, Shu-Lian Wang, Xin-Fan Liu, Li-Qiang Zhou, Xiao-Hui He, Ning Lu, Zi-Hao Yu.   

Abstract

UNLABELLED: PURPOSE The optimal therapy remains unclear for nasal natural killer (NK)/T-cell lymphoma. The purpose of this study is to analyze the outcome of radiotherapy as the primary treatment for localized stage IE and IIE diseases. PATIENTS AND METHODS: One hundred five patient cases were reviewed. There were 83 stage IE and 22 stage IIE patients. All except three patients received radiotherapy (RT) alone or RT combined with chemotherapy (CT; combined-modality therapy [CMT]). Overall, 31 patients were treated with RT alone, 34 with RT followed by CT, 37 with CT followed by RT, and three with CT alone.
RESULTS: Five-year overall survival (OS) and progression-free survival (PFS) for all patients were 71% and 59%, respectively. The 5-year OS and PFS were 78% and 63% for stage IE, and 46% and 40% for stage IIE, respectively. Complete response (CR) was achieved in 91 patients (87%) after RT and/or CT. Initial RT resulted in a superior CR as compared with initial CT, with 54 (83%) of 65 patients achieving CR with initial RT, versus only eight (20%) of 40 after initial CT. For 102 patients who received RT with or without CT, the outcome of primary treatment with RT alone was compared with that of CMT. Five-year OS and PFS was 66% and 61% for RT alone, and 76% and 61%% for CMT, respectively (OS, P = .6433; PFS, P = .8391).
CONCLUSION: RT as primary therapy resulted in good outcome in early-stage disease, and the addition of CT to RT was not accompanied by an improvement in survival.

Entities:  

Mesh:

Year:  2006        PMID: 16382127     DOI: 10.1200/JCO.2005.03.2573

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  98 in total

1.  Lymphopenia during routine follow-up may predict relapse in patients with extranodal NK/T cell lymphoma.

Authors:  Liang Wang; Jing-hua Wang; Zhi-jun Wu-Xiao; Zhong-jun Xia; Hui-qiang Huang; Yue Lu
Journal:  Tumour Biol       Date:  2014-10-31

2.  Primary duodenal NK/T-cell lymphoma with massive bleeding: A case report.

Authors:  Jian-Zhong Li; Jin Tao; Dan-Yun Ruan; Yi-Dong Yang; Ya-Shi Zhan; Xing Wang; Yu Chen; Si-Chi Kuang; Chun-Kui Shao; Bin Wu
Journal:  World J Clin Oncol       Date:  2012-06-10

3.  Novel therapies for peripheral T-cell lymphomas.

Authors:  Andrei Shustov
Journal:  Ther Adv Hematol       Date:  2013-06

4.  NK/T Cell Lymphoma: A Tertiary Centre Experience.

Authors:  Neeraj Arora; Arpan Mehta; Sriram Ravichandran; Indu Arun; Rimpa Basu Achari; Anupam Chakrapani; Saurabh Jayant Bhave; Mammen Chandy; Reena Nair
Journal:  Indian J Hematol Blood Transfus       Date:  2016-04-21       Impact factor: 0.900

5.  Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.

Authors:  Hui-Hui Ma; Li-Ting Qian; Hai-Feng Pan; Lin Yang; Hong-Yan Zhang; Zhi-Hua Wang; Jun Ma; Yu-Fei Zhao; Jin Gao; Ai-Dong Wu
Journal:  Med Oncol       Date:  2009-08-15       Impact factor: 3.064

6.  Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.

Authors:  Y Q Wang; Y Yang; H Y Zhuo; L Q Zou; Y Jiang; M Jiang
Journal:  Med Oncol       Date:  2015-01-09       Impact factor: 3.064

7.  Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study.

Authors:  Y Yang; Y-J Zhang; Y Zhu; J-Z Cao; Z-Y Yuan; L-M Xu; J-X Wu; W Wang; T Wu; B Lu; S-Y Zhu; L-T Qian; F-Q Zhang; X-R Hou; Q-F Liu; Y-X Li
Journal:  Leukemia       Date:  2015-02-20       Impact factor: 11.528

8.  A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Authors:  Christopher P Fox; Tracey A Haigh; Graham S Taylor; Heather M Long; Steven P Lee; Claire Shannon-Lowe; Simon O'Connor; Catherine M Bollard; Javeed Iqbal; Wing C Chan; Alan B Rickinson; Andrew I Bell; Martin Rowe
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

Review 9.  Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.

Authors:  Holbrook Kohrt; Ranjana Advani
Journal:  Leuk Lymphoma       Date:  2009-11

Review 10.  Current and future management of NK/T-cell lymphoma based on clinical trials.

Authors:  Motoko Yamaguchi
Journal:  Int J Hematol       Date:  2012-10-17       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.